Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Immunosuppressants Stories

2013-03-21 04:20:42

-- Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS1 EAST HANOVER, N.J., March 21, 2013 /PRNewswire/ -- New data presented at the 65th annual meeting of the American Academy of Neurology (AAN) show Gilenya(®) (fingolimod), the first oral disease modifying therapy approved to treat relapsing forms of multiple sclerosis (MS), significantly and consistently...

2013-03-18 08:30:03

NEW YORK, March 18, 2013 /PRNewswire/ -- Today, Wall Street Source announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Sinovac Biotech Ltd. (NASDAQ: SVA), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Gilead Sciences, Inc....

2013-03-13 08:33:45

Development License and Option Agreement Represents Blueprint for Innovation between Pharma and Biotech SAN DIEGO, March 13, 2013 /PRNewswire/ -- Receptos Inc. announced today that it has entered a Development License and Option Agreement to in-license a humanized anti-interleukin-13 (IL-13) antibody asset from AbbVie (NYSE: ABBV). The asset, designated RPC4046 by Receptos, has completed a first-in-human Phase I study. Under the agreement, Receptos will conduct a Phase 2 clinical...

2013-03-11 13:22:56

The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. The study examined 319 people with MS who were treated with...

2013-03-11 08:26:46

LUND, Sweden, March 11, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, announces it has completed the acquisition of a portfolio of novel cyclophilin inhibitors, technology platform assets and related intellectual property rights from the UK biotech company Biotica Ltd. The acquisition of these assets is important strategically as it will allow NeuroVive to broaden and deepen its pipeline of novel mitochondrial medicines. No financial details of the...

2013-03-10 23:01:33

The http://www.SclerosisTreatment.com website, a division of Ironclad Integrity Ltd., reveals a new therapy based on plants, vitamins and correct nutrition to reduce fatigue, pain and other MS symptoms instead of drug intake. Denver, Colorado (PRWEB) March 10, 2013 According to http://www.Sclerosistreatment.com for the 2.5 million MS patients worldwide, the lack of a permanent cure for their condition is frustrating and puzzling. Conventional therapies to treat Multiple Sclerosis are based...

2013-03-10 16:20:35

SAN DIEGO, March 10, 2013 /PRNewswire-USNewswire/ -- The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. The study...

2013-03-10 12:20:23

Separate Study Demonstrates PROMUS Element Stent has Significantly Less Vessel Straightening than the Xience V® Stent NATICK, Mass., March 10, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reported clinical endpoint data from the PLATINUM workhorse clinical trial comparing the safety and effectiveness of the PROMUS Element(TM) Everolimus-Eluting Platinum Chromium (PtCr) Coronary Stent System to the Cobalt Chromium (CoCr) Xience V® Everolimus-Eluting Coronary...

2013-03-07 23:51:30

26 countries can't afford certain disease modifying drugs, so excluding 320 million people This means that 320 million people - 40% of Europe's population - who could benefit from treatment with disease modifying drugs (DMARDs) would struggle to get access to them, say the researchers. DMARDs are extremely effective for the treatment of rheumatoid arthritis, and the European League Against Rheumatism (EULAR) recommends the use of synthetic DMARDs immediately after diagnosis to halt...

2013-03-05 12:28:06

EXTON, Pa., March 5, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, although there have been no significant changes with regard to biologic treatment and Crohn's disease (CD) patients with active disease since 2012, surveyed gastroenterologist data indicate a significant 43 percent increase in biologic treatment among CD patients in remission since 2012, suggesting that biologic agents...